[Asia Economy Reporter Hyunseok Yoo] ToBeSoft is showing strong performance. It is interpreted that this is due to being highlighted as a beneficiary stock of the vaccine cold chain caused by the novel coronavirus infection (COVID-19).
As of 9:05 AM on the 11th, ToBeSoft was trading at 2,415 KRW, up 4.09% (95 KRW) compared to the previous trading day.
Following the flu vaccine phobia, on the 9th (local time), global pharmaceutical company Pfizer announced positive interim results of Phase 3 clinical trials for the COVID-19 vaccine, raising interest in vaccine production, storage, and transportation. Pfizer's vaccine is known to be storable for only 5 days at minus 70 degrees Celsius.
ToBeSoft is participating in the Ministry of Trade, Industry and Energy's national project, the "2019 Knowledge Service Industry Core Technology Development Project," developing an AI (artificial intelligence)-based pharmaceutical cold chain platform.
The pharmaceutical cold chain platform under development is an intelligent cloud cold chain platform service. Compared to existing cold chain systems, it offers higher safety, transparency, and cost reduction effects during the distribution process.
The cold chain refers to a low-temperature logistics system that maintains the entire process of production, storage, distribution, and sales at low temperatures to manage the quality of temperature-sensitive product groups such as fresh food and pharmaceuticals. Among them, vaccines and biopharmaceuticals are much more sensitive to temperature, requiring refrigerated distribution mostly at 2 to 8 degrees Celsius and some ultra-low temperature frozen storage.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
